HC Wainwright & Co. Maintains Buy on Altimmune, Raises Price Target to $25
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Altimmune (NASDAQ:ALT) with a Buy and raises the price target from $12 to $25.
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Altimmune (NASDAQ:ALT) with a Buy and raises the price target from $12 to $25.